CSIMarket
 
Eiger Biopharmaceuticals Inc   (EIGR)
 

The company reported a superb rise, amid the fiscal time-frame ending March 31 2023

Eiger Biopharmaceuticals Inc reported first quarter of 2023 operating shortfall of $-22.263 million


Published 2023-05-14T07:26:56+00:00
Goran Soko / CSIMarket.com Contributer


pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_CommonsFor the most recent fiscal period Eiger Biopharmaceuticals Inc lost money of $-0.52 per share compare to $-0.64 a year before and advanced deficit from $-0.46 per share from the preceding reporting period.

The revenue grew strongly by 54.059 % to $4.12 million from $2.67 million in the same reporting period a year before and sequentially revenue surged by 52.745 % from $2.70 million.




For the most recent fiscal period Eiger Biopharmaceuticals Inc realized net deficit of $-22.784 million, larger than $-22.643 million a year ago.


Eiger Biopharmaceuticals Inc is expected to report next financial recent numbers on August 03, 2023.



Eiger Biopharmaceuticals Inc's Operating Margin

Eiger Biopharmaceuticals Inc's ROE



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071